Breaking News Instant updates and real-time market news.

AMRN

Amarin

$21.03

-0.26 (-1.22%)

13:24
11/11/18
11/11
13:24
11/11/18
13:24

Amarin announced primary results from Vascepa cardiovascular outcomes trial

Amarin announced the primary results from the Vascepa cardiovascular outcomes trial, REDUCE-IT, following presentation of the late-breaking clinical trial results at the 2018 Scientific Sessions of the American Heart Association in Chicago, Illinois. REDUCE-IT primary results confirmed 25% relative risk reduction for the topline primary endpoint result with multiple robust demonstrations of efficacy, including 20% reduction in cardiovascular death. Cardiovascular benefits appeared not to be influenced significantly by triglyceride levels at baseline or as achieved at one year, suggesting mechanisms at work with use of Vascepa that are independent of triglyceride reduction. Results were robust across multiple subgroups, including in patients with and without diabetes at baseline. REDUCE-IT was a global study of 8,179 statin-treated adults with elevated CV risk. Many patients with well-managed LDL-C remain at high risk for cardiovascular events. No therapy is currently approved to treat the residual risk in REDUCE-IT patients and no other therapy has demonstrated a 25% risk reduction on top of statin therapy in a major cardiovascular outcomes trial. REDUCE-IT studied Vascepa 4 grams/day as compared to placebo over a median follow-up time of 4.9 years. The REDUCE-IT study was designed under a special protocol assessment agreement with the U.S. Food and Drug Administration. Amarin intends to submit an sNDA to the FDA in early 2019 seeking approval to expand the label for Vascepa based on the cardioprotective effect of Vascepa demonstrated in the REDUCE-IT study. FDA's determination of standard or priority review will be made when the sNDA is submitted. At this time, Amarin is planning for a standard review with potential approval anticipated in late 2019. Vascepa is a low-cost drug. The majority of patients covered by insurance who obtain prescriptions for Vascepa pay a monthly co-pay charge of $9.99 or less. A patient with commercial insurance can pay as little as $9 for a 90-day supply prescription of Vascepa.

AMRN Amarin
$21.03

-0.26 (-1.22%)

11/02/18
SBSH
11/02/18
DOWNGRADE
Target $28
SBSH
Neutral
Citi now sees limited upside in Amarin, downgrades to Neutral
Citi analyst Joel Beatty downgraded Amarin to Neutral from Buy while raising his price target for the shares to $28 from $25. The analyst still believe that Vascepa is an attractive drug that will exceed $3B in sales. However, he thinks investor expectations have increased substantially over recent weeks, "such that upside is likely to be limited over the coming months, with the possible exception of an acquisition."
11/05/18
RHCO
11/05/18
NO CHANGE
Target $30
RHCO
Buy
Amarin price target raised to $30 from $15 at SunTrust
SunTrust analyst John Boris raised his price target on Amarin to $30 and kept his Buy rating, saying its REDUCE-IT data on Vascepa at the upcoming American Heart Association meeting its expected to show "unprecedented benefits in sub-populations & decrease in hospitalizations". The analyst models the program's sales at $2.5B in 2024 amid a "paradigm shift" in therapy with a long post-loss of exclusivity tail comparable to that of Lovaza.
11/08/18
JEFF
11/08/18
INITIATION
Target $30
JEFF
Buy
Amarin assumed with a Buy at Jefferies
Jefferies analyst Michael Yee assumed coverage of Amarin with a Buy rating and $30 price target. The analyst sees "semi-high expectations" going into the American Heart Association meeting but he believes investors will come away after the event saying the "data looks good." Further, Amarin is a potential takeover candidate going into 2019 "so the path to least resistance is higher," Yee tells investors in a research note. Based on industry fundamentals Amarin represents "one of only a handful of scarce M&A assets for big pharma and existing pharma metabolic-focused salesforce," says Yee.
11/08/18
11/08/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Stanley Black & Decker (SWK) initiated with a Hold at Deutsche Bank. 2. Comcast (CMCSA) resumed with an Overweight at Morgan Stanley while Amarin (AMRN) and Immunomedics (IMMU) were assumed with a Buy at the firm. 3. Broadcom (AVGO) resumed with a Buy at Deutsche Bank and reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

MKL

Markel

$1,067.03

13.52 (1.28%)

16:36
01/18/19
01/18
16:36
01/18/19
16:36
Hot Stocks
Markel says Anthony Belisle, Alissa Fredricks no longer with company »

Markel Corporation said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NILSY

Norilsk Nickel

$0.00

(0.00%)

16:35
01/18/19
01/18
16:35
01/18/19
16:35
Downgrade
Norilsk Nickel rating change  »

Norilsk Nickel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

, ABBV

AbbVie

$89.51

2.28 (2.61%)

16:33
01/18/19
01/18
16:33
01/18/19
16:33
Hot Stocks
AbbVie: Phase 3 study of ibrutinib did not meet primary endpoint »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

ABBV

AbbVie

$89.51

2.28 (2.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 27

    Jan

  • 28

    Jan

  • 18

    Feb

  • 18

    May

FOMX

Foamix

$3.70

-0.14 (-3.65%)

16:32
01/18/19
01/18
16:32
01/18/19
16:32
Conference/Events
Foamix to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

16:30
01/18/19
01/18
16:30
01/18/19
16:30
Options
Preliminary option volume of 26.9M today »

Preliminary option volume…

NBRV

Nabriva Therapeutics

$1.97

-0.01 (-0.51%)

16:27
01/18/19
01/18
16:27
01/18/19
16:27
Conference/Events
Nabriva Therapeutics to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Apr

VLRS

Volaris

$7.50

0.04 (0.54%)

16:21
01/18/19
01/18
16:21
01/18/19
16:21
Conference/Events
International Aviation Club to host monthly luncheon meeting »

Enrique Beltranena, CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
01/18/19
01/18
16:20
01/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for January 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/18/19
01/18
16:17
01/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/18/19
01/18
16:16
01/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$14.48

-0.57 (-3.79%)

16:14
01/18/19
01/18
16:14
01/18/19
16:14
Conference/Events
Forty Seven to hold KOL breakfast symposium »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$302.26

-45.18 (-13.00%)

, WMT

Walmart

$97.75

1.01 (1.04%)

16:14
01/18/19
01/18
16:14
01/18/19
16:14
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks opened higher and…

TSLA

Tesla

$302.26

-45.18 (-13.00%)

WMT

Walmart

$97.75

1.01 (1.04%)

CVS

CVS Health

$65.49

2.13 (3.36%)

NFLX

Netflix

$339.20

-14.02 (-3.97%)

FB

Facebook

$150.01

1.77 (1.19%)

AAPL

Apple

$156.85

0.99 (0.64%)

QCOM

Qualcomm

$55.26

0.44 (0.80%)

FND

Floor & Decor

$31.99

2.34 (7.89%)

OZK

Bank OZK

$32.07

4.47 (16.20%)

VFC

VF Corp.

$82.39

9.135 (12.47%)

NLS

Nautilus

$7.00

-4.76 (-40.48%)

CASA

Casa Systems

$11.23

-3.17 (-22.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

SNE

Sony

$50.08

0.58 (1.17%)

16:12
01/18/19
01/18
16:12
01/18/19
16:12
Periodicals
Sony Music ends working relationship with R. Kelly, Variety reports »

Sony Music has opted to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$64.58

0.53 (0.83%)

16:12
01/18/19
01/18
16:12
01/18/19
16:12
Hot Stocks
Prologis, Ivanhoe Cambridge form $880M joint venture in Brazil »

Prologis and Ivanhoe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CYDY

CytoDyn

$0.00

(0.00%)

16:10
01/18/19
01/18
16:10
01/18/19
16:10
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHF

WhiteHorse Finance

$13.58

-0.105 (-0.77%)

16:09
01/18/19
01/18
16:09
01/18/19
16:09
Hot Stocks
WhiteHorse Finance, STRS Ohio form JV to invest in debt facilities »

WhiteHorse Finance, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$133.43

0.6 (0.45%)

16:07
01/18/19
01/18
16:07
01/18/19
16:07
Hot Stocks
Chubb sees Q4 net catastrophe loss approximately $585M pre-tax, $505M after tax »

Chubb announced net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

ESEA

Euroseas

$0.80

-0.0332 (-3.98%)

16:07
01/18/19
01/18
16:07
01/18/19
16:07
Hot Stocks
Euroseas receives Nasdaq notice of non-compliance »

Euroseas Ltd. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$75.68

0.08 (0.11%)

, SSNLF

Samsung

$0.00

(0.00%)

16:04
01/18/19
01/18
16:04
01/18/19
16:04
Hot Stocks
FDA approves Samsung Bioepis-Merck biosimilar to Roche's Herceptrin »

The FDA announced that it…

MRK

Merck

$75.68

0.08 (0.11%)

SSNLF

Samsung

$0.00

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 28

    Jan

  • 01

    Feb

  • 16

    Feb

  • 18

    Mar

  • 11

    Apr

  • 18

    May

NKE

Nike

$80.35

1.23 (1.55%)

15:40
01/18/19
01/18
15:40
01/18/19
15:40
Options
Nike calls lead puts more than 4:1 as shares extend gains »

Nike calls lead puts more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANIX

Anixa Biosciences

$4.20

-0.05 (-1.18%)

15:37
01/18/19
01/18
15:37
01/18/19
15:37
Conference/Events
Anixa Biosciences to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

15:25
01/18/19
01/18
15:25
01/18/19
15:25
General news
SF Fed president Daly advocated a pause »

SF Fed president Daly…

ESTA

Establishment Labs

$26.40

-0.51 (-1.90%)

15:22
01/18/19
01/18
15:22
01/18/19
15:22
Hot Stocks
RTW Investments reports 5.13% passive stake in Establishment Labs »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATEN

A10 Networks

$6.63

0.205 (3.19%)

15:20
01/18/19
01/18
15:20
01/18/19
15:20
Options
A10 Networks attracts put sellers as shares extend gains »

A10 Networks attracts put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

EQT

EQT Corporation

$21.09

0.135 (0.64%)

15:18
01/18/19
01/18
15:18
01/18/19
15:18
Conference/Events
EQT Corporation to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.